Monaco Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Monaco Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,923	Closed	-$59.6K	–	58
2023 Q4	$59.6K	Buy	7,923 +2,000	+34%	+$18.3K	0.02%	78
2023 Q3	$88.9K	Sell	5,923 -17,577	-75%	-$316K	0.03%	71
2023 Q2	$374K	Sell	23,500 -42,458	-64%	-$446K	0.1%	60
2023 Q1	$473K	Hold	65,958	–	–	0.15%	56
2022 Q4	$382K	Buy	65,958 +43,458	+193%	+$330K	0.12%	69
2022 Q3	$214K	Sell	22,500 -22,200	-50%	-$292K	0.08%	65
2022 Q2	$536K	Buy	+44,700	New	+$468K	0.23%	52

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Monaco Asset Management's ADVM Position: Q1 2024 in Review

Monaco Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2024, closing a stake of 7,923 shares — an estimated $59.6K sold.

Monaco Asset Management first reported a position in ADVM in Q2 2022 and held it in 7 quarters. The position peaked at $536K in Q2 2022. 61 funds tracked by Wall St. Rank hold ADVM as of Q1 2024.

Monaco Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2024 after selling out during the quarter.
Monaco Asset Management sold 7,923 Adverum Biotechnologies shares in Q1 2024, an estimated $59.6K.
Monaco Asset Management first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 7 quarters.
Monaco Asset Management's Adverum Biotechnologies position peaked at $536K in Q2 2022.
61 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2024.

Based on Monaco Asset Management's 13F filing for Q1 2024, filed 9 May 2024.